Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Quarterly Earnings Results, Misses Estimates By $0.47 EPS

04 Aug 2026, 00:10 by Tristan Rich · The Markets Daily

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) posted its quarterly earnings data on Monday. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47), FiscalAI reports. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. During the same quarter in the prior year, the firm posted ($8.25) EPS. Jazz Pharmaceuticals’s quarterly revenue was up 15.5% compared to the same quarter last year.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

Record revenue of $1.21 billion rose 16% year over year, prompting Jazz to raise 2026 revenue guidance to $4.60 billion–$4.75 billion. Adjusted EPS was $5.71, while first-half operating cash flow reached $824 million.
XYWAV sales increased 13% to $471 million, with approximately 525 net patient additions and limited uptake of high-sodium generics. Jazz now expects double-digit XYWAV growth in 2026 and raised rare-sleep revenue guidance to $2.025 billion–$2.125 billion.
Epidiolex sales grew 16% to $292 million on strong underlying demand, particularly among adult and long-term-care patients. Jazz is pursuing a capsule formulation and several clinical trials to expand usage across additional treatment-resistant seizure populations.
Jazz expressed high confidence in zanidatamab’s approval for first-line HER2-positive metastatic GEA by the August 25 PDUFA date and said it is prepared for launch. The company highlighted median overall survival of 26.4 months in the combination arm and expects additional doublet overall-survival data in the third quarter.
Zepzelca sales rose 42% to $106 million, driven by first-line maintenance adoption, but Jazz plans to submit a labeling supplement removing the second-line indication after the LAGOON results. Management expects the historical second-line business to continue eroding, with a possible acceleration following the label change.

Jazz Pharmaceuticals Trading Down 0.5%

JAZZ stock traded down $1.28 during trading on Monday, hitting $251.58. The company had a trading volume of 1,493,225 shares, compared to its average volume of 948,321. Jazz Pharmaceuticals has a 12 month low of $105.00 and a 12 month high of $261.30. The stock has a market cap of $15.80 billion, a price-to-earnings ratio of -12,572.71, a PEG ratio of 0.22 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The firm has a 50-day moving average price of $239.50 and a 200-day moving average price of $207.30.

Insiders Place Their Bets

In related news, Director Rick E. Winningham sold 2,741 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark Douglas Smith sold 1,157 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $230.55, for a total transaction of $266,746.35. Following the sale, the director directly owned 9,680 shares in the company, valued at $2,231,724. This trade represents a 10.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,098 shares of company stock worth $3,131,906 in the last three months. 4.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of JAZZ. Ameriprise Financial Inc. increased its holdings in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after acquiring an additional 191,637 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in Jazz Pharmaceuticals by 3.1% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company’s stock valued at $285,113,000 after acquiring an additional 50,996 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $127,344,000. Bank of America Corp DE lifted its stake in shares of Jazz Pharmaceuticals by 8.7% during the 2nd quarter. Bank of America Corp DE now owns 1,052,470 shares of the specialty pharmaceutical company’s stock valued at $111,688,000 after buying an additional 83,937 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 25.5% in the fourth quarter. AQR Capital Management LLC now owns 877,267 shares of the specialty pharmaceutical company’s stock valued at $149,135,000 after purchasing an additional 178,326 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the topic of several analyst reports. Barclays lifted their target price on Jazz Pharmaceuticals from $253.00 to $260.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Needham & Company LLC raised their price target on shares of Jazz Pharmaceuticals from $255.00 to $282.00 and gave the company a “buy” rating in a report on Monday, July 20th. Robert W. Baird set a $252.00 price objective on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Morgan Stanley restated an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Finally, TD Cowen lifted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $259.06.

Check Out Our Latest Stock Analysis on JAZZ

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.